Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


March 26, 2015 4:07 PM ET

Pharmaceuticals

Company Overview of Zentiva NV

Company Overview

Zentiva N.V. develops, manufactures, and markets branded generic pharmaceutical products. The company provides generic drugs, cosmetics, and pharmaceutical substances. It offers products in various therapeutic areas, including cardiovascular diseases, disorders of central nervous system, digestion system, diabetes, inflammatory conditions, pain, infection, gastrointestinal, urinary tract and genital system, and treatment of respiratory diseases. In addition, the company provides dietary supplements and active pharmaceutical ingredients. Zentiva NV sells its pharmaceutical products in the Czech Republic, Turkey, Romania, Slovakia, Poland, and Russia, as well as in Ukraine, the Baltic States, ...

Fred Roeskestraat 123

Amsterdam,  1076 EE

Netherlands

Founded in 1998

6,000 Employees

Phone:

31 20 673 9753

Fax:

31 20 470 8362

Key Executives for Zentiva NV

Chief Financial Officer and Vice President
Age: 53
Chief Operating Officer
Age: 54
Head of IA and Development
Age: 59
General Counsel
Compensation as of Fiscal Year 2014.

Zentiva NV Key Developments

Zentiva NV Announces Preliminary Earnings Results for the Year 2014

Zentiva NV announced preliminary earnings results for the year 2014. For the year, the company reported net profit of RON 61.5 million against RON 40.3 million a year ago. Operating profit RON 75.4 million against RON 50.6 million a year ago. Net turnover was RON 395.8 million against RON 290.4 a year ago.

Zentiva NV Announces Earnings Results for the First Half of 2014

Zentiva NV announced earnings results for the first half of 2014. For the period, the company reported net profit of RON 27.17 million compared with RON 28.35 million for the same period a year ago. Operating profit was RON 33.80 million compared with RON 33.50 million for the same period a year ago. Net turnover was RON 200.13 million compared with RON 160.86 million for the same period a year ago. Total revenue was RON 205.35 million compared with RON 162.05 million for the same period a year ago.

Zentiva Reports Earnings Results for the First Half of 2013

Zentiva reported earnings results for the first half of 2013. The company's net profit rose to RON 28.35 million ($8.5 million/€6.4 million) in the first half of 2013 from RON 21.24 million a year earlier. Operating profit was RON 33.50 million, compared to RON 24.66 million a year earlier. Net turnover was RON 160.86 million, compared to RON 139.37 million a year earlier. Total revenue was RON 162.05 million, compared to RON 153 million a year earlier.

Similar Private Companies By Industry

Company Name Region
BioActor B.V. Europe
DCPrime B.V. Europe
IQ Therapeutics BV Europe
Banner Pharmacaps Europe B.V. Europe
Centrafarm Nederland B.V. Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Zentiva NV, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.